Inflammatory proteins associated with Alzheimer’s disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial

Abstract Background Glucagon-like peptide-1 receptor agonists are a viable option for the prevention of Alzheimer’s disease (AD) but the mechanisms of this potential disease modifying action are unclear. We investigated the effects of once-weekly exenatide (EQW) on AD associated proteomic clusters....

ver descrição completa

Detalhes bibliográficos

Principais autores:	Ivan Koychev, Graham Reid, Maggie Nguyen, Robert J. Mentz, Dan Joyce, Svati H. Shah, Rury R. Holman
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2024-10-01
coleção:	Alzheimer’s Research & Therapy
Assuntos:	Alzheimer’s disease Glucagon-like peptide-1 receptor agonists Proteomics
Acesso em linha:	https://doi.org/10.1186/s13195-024-01573-x
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!